News
03-30-2011, 11:10 AM
ExonHit Therapeutics (Paris:ALEHT) today announced successful completion of the first phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones...
More... (http://www.medicalnewstoday.com/articles/220711.php)
More... (http://www.medicalnewstoday.com/articles/220711.php)